Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK. Kamoun WS, et al. Among authors: lahdenranta j. J Clin Oncol. 2009 May 20;27(15):2542-52. doi: 10.1200/JCO.2008.19.9356. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332720 Free PMC article.
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. Sorensen AG, et al. Among authors: lahdenranta j. Cancer Res. 2009 Jul 1;69(13):5296-300. doi: 10.1158/0008-5472.CAN-09-0814. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549889 Free PMC article.
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Willett CG, et al. Among authors: lahdenranta j. J Clin Oncol. 2009 Jun 20;27(18):3020-6. doi: 10.1200/JCO.2008.21.1771. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470921 Free PMC article. Clinical Trial.
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Zhu AX, et al. Among authors: lahdenranta j. J Clin Oncol. 2009 Jun 20;27(18):3027-35. doi: 10.1200/JCO.2008.20.9908. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470923 Free PMC article.
Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.
Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R. Kolonin MG, et al. Among authors: lahdenranta j. Cancer Res. 2006 Jan 1;66(1):34-40. doi: 10.1158/0008-5472.CAN-05-2748. Cancer Res. 2006. PMID: 16397212
36 results